NovoCure (NASDAQ:NVCR) Price Target Raised to $52.00 at HC Wainwright

NovoCure (NASDAQ:NVCR) had its price target hoisted by HC Wainwright from $46.00 to $52.00 in a research report released on Thursday morning, Marketbeat.com reports. They currently have a buy rating on the medical equipment provider’s stock.

Several other research firms have also issued reports on NVCR. Weiss Ratings upgraded NovoCure from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 1st. Zacks Research downgraded shares of NovoCure from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Wedbush reaffirmed a “neutral” rating and issued a $18.00 target price on shares of NovoCure in a report on Thursday, April 16th. Wells Fargo & Company increased their target price on shares of NovoCure from $13.50 to $17.00 and gave the stock an “equal weight” rating in a research report on Monday, May 4th. Finally, Evercore reissued an “outperform” rating on shares of NovoCure in a report on Friday, May 1st. Two analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, NovoCure currently has an average rating of “Hold” and a consensus target price of $24.80.

NovoCure Trading Up 28.4%

NVCR stock opened at $19.99 on Thursday. NovoCure has a 1-year low of $9.82 and a 1-year high of $20.55. The company has a current ratio of 2.90, a quick ratio of 2.70 and a debt-to-equity ratio of 0.71. The business’s 50 day moving average is $16.64 and its 200-day moving average is $14.12. The firm has a market cap of $2.32 billion, a P/E ratio of -13.07 and a beta of 0.94.

NovoCure (NASDAQ:NVCR) last posted its earnings results on Thursday, July 23rd. The medical equipment provider reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.20. The business had revenue of $183.58 million during the quarter, compared to the consensus estimate of $172.44 million. NovoCure had a negative return on equity of 50.82% and a negative net margin of 25.66%.NovoCure’s revenue was up 15.6% on a year-over-year basis. During the same quarter last year, the company earned ($0.36) EPS. Equities analysts anticipate that NovoCure will post -1.52 earnings per share for the current fiscal year.

Insider Transactions at NovoCure

In other news, Director Timothy J. Scannell sold 2,945 shares of the firm’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $15.77, for a total value of $46,442.65. Following the completion of the sale, the director directly owned 14,288 shares in the company, valued at approximately $225,321.76. This trade represents a 17.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeryl L. Hilleman sold 2,945 shares of NovoCure stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $15.77, for a total value of $46,442.65. Following the completion of the transaction, the director directly owned 13,861 shares of the company’s stock, valued at $218,587.97. This represents a 17.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 51,943 shares of company stock worth $893,171. 5.52% of the stock is owned by company insiders.

Institutional Investors Weigh In On NovoCure

Hedge funds have recently added to or reduced their stakes in the stock. Handelsbanken Fonder AB increased its position in NovoCure by 37.2% in the 2nd quarter. Handelsbanken Fonder AB now owns 51,223 shares of the medical equipment provider’s stock valued at $776,000 after acquiring an additional 13,900 shares in the last quarter. Amundi lifted its position in shares of NovoCure by 19.9% during the first quarter. Amundi now owns 47,583 shares of the medical equipment provider’s stock worth $519,000 after purchasing an additional 7,907 shares in the last quarter. California State Teachers Retirement System lifted its position in shares of NovoCure by 43.6% during the first quarter. California State Teachers Retirement System now owns 142,561 shares of the medical equipment provider’s stock worth $1,554,000 after purchasing an additional 43,257 shares in the last quarter. Eversept Partners LP grew its stake in shares of NovoCure by 11.5% during the first quarter. Eversept Partners LP now owns 134,917 shares of the medical equipment provider’s stock valued at $1,471,000 after purchasing an additional 13,939 shares during the last quarter. Finally, Quantinno Capital Management LP grew its stake in shares of NovoCure by 23.7% during the first quarter. Quantinno Capital Management LP now owns 2,487,376 shares of the medical equipment provider’s stock valued at $27,112,000 after purchasing an additional 477,128 shares during the last quarter. Institutional investors own 84.61% of the company’s stock.

Key Stories Impacting NovoCure

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: NovoCure reported Q2 earnings that beat expectations, with a loss of $0.13 per share versus the expected $0.33 loss, while revenue of $183.58 million also topped estimates and grew 15.6% year over year. Article Title
• Positive Sentiment: The company also issued FY 2026 revenue guidance of $710 million to $725 million, above the consensus estimate of about $704 million, which suggests management sees continued top-line momentum. Article Title
• Positive Sentiment: HC Wainwright raised its price target on NovoCure to $52 from $46 and reiterated a Buy rating, reinforcing the bullish view after the earnings release. Article Title
• Neutral Sentiment: Additional coverage highlighted NovoCure’s Q2 results and a possible technical breakout, which may be adding to investor optimism but does not change the underlying fundamentals. Article Title

About NovoCure

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.